These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3473163)

  • 1. Tumor immunoglobulin with antibody activity against blood coagulation factors.
    Antonucci M; Berard M; Beaumont JL
    J Med; 1986; 17(3-4):149-65. PubMed ID: 3473163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant activity in cell-free peritoneal fluid of an experimental pancreatic ascites tumor.
    Ts'ao C; Galluzzo TS; Hart SJ; Ng AS; Sorenson PG; Subbarao V
    Thromb Haemost; 1985 Dec; 54(4):768-72. PubMed ID: 3003955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
    Brecher AS; Hellman K; Basista MH
    Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of various anticoagulants on blood coagulation: with special reference to false positive lupus anticoagulants].
    Onda H; Watanabe H
    Rinsho Byori; 1989 Dec; 37(12):1385-91. PubMed ID: 2515325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of protamine of the prolonged response to intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
    Torjemane L; Guermazi S; Ladeb S; Ben Romdhane N; Lakhal A; Abdelkefi A; Ben Othman T; Ben Abdelhadhim A
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):279-81. PubMed ID: 17413766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity.
    Brecher AS; Fu Q
    J Investig Med; 1999 Jan; 47(1):76-80. PubMed ID: 10071484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the anticoagulant action of heparin, protamine, and Polybrene in the activation of factor IX.
    Shanberge JN; Fukui H
    J Lab Clin Med; 1967 Jun; 69(6):927-37. PubMed ID: 6025496
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitigation of coagulation by removing clotting factors part 2: heparin-free extracorporeal circulation in a porcine model.
    Sukavaneshvar S; Parker JT; Beutler DS; Burns G; Solen KA; Mohammad SF
    ASAIO J; 2007; 53(4):421-7. PubMed ID: 17667225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigation of coagulation by removing clotting factors part 1: in vitro feasibility study.
    Parker JT; Beutler DS; Sukavaneshvar S; Jacobs N; Solen KA; Mohammad SF
    ASAIO J; 2007; 53(4):415-20. PubMed ID: 17667224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1984 Apr; 51(2):266-8. PubMed ID: 6740558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage.
    Perkash A
    Am J Clin Pathol; 1980 May; 73(5):676-81. PubMed ID: 7377134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A patient with hemorrhage originating from an unknown coagulation pathway inhibitor].
    Komiyama Y; Munakata M; Masuda M; Kagawa H; Fukuhara S; Takahashi H
    Rinsho Byori; 2000 Dec; 48(12):1086-92. PubMed ID: 11215416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of regulating blood clotting with heparin and its antagonists on mast cells].
    Efimov VS; Rozkin MIa; Poberiĭ IA; Lindner DP
    Farmakol Toksikol; 1981; 44(1):80-5. PubMed ID: 7262304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis.
    Bykowska K; Ludwicka A; Wegrzynowicz Z; Lopaciuk S; Kopeć M
    Thromb Haemost; 1985 Dec; 54(4):853-6. PubMed ID: 4089818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.